Maneka Mirchandaney
Stock Analyst at Evercore ISI Group
(0.26)
# 4,343
Out of 5,044 analysts
7
Total ratings
28.57%
Success rate
-28.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maneka Mirchandaney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $41 → $48 | $42.06 | +14.12% | 2 | Sep 11, 2023 | |
| INKT MiNK Therapeutics | Maintains: Outperform | $40 → $30 | $14.20 | +111.34% | 2 | Mar 22, 2023 | |
| INCY Incyte | Downgrades: In-Line | $90 → $78 | $91.65 | -14.89% | 1 | Aug 3, 2022 | |
| VRDN Viridian Therapeutics | Initiates: Outperform | $40 | $23.17 | +72.64% | 1 | Oct 12, 2021 | |
| HOWL Werewolf Therapeutics | Initiates: Outperform | $23 | $1.62 | +1,319.75% | 1 | May 25, 2021 |
Crinetics Pharmaceuticals
Sep 11, 2023
Maintains: Outperform
Price Target: $41 → $48
Current: $42.06
Upside: +14.12%
MiNK Therapeutics
Mar 22, 2023
Maintains: Outperform
Price Target: $40 → $30
Current: $14.20
Upside: +111.34%
Incyte
Aug 3, 2022
Downgrades: In-Line
Price Target: $90 → $78
Current: $91.65
Upside: -14.89%
Viridian Therapeutics
Oct 12, 2021
Initiates: Outperform
Price Target: $40
Current: $23.17
Upside: +72.64%
Werewolf Therapeutics
May 25, 2021
Initiates: Outperform
Price Target: $23
Current: $1.62
Upside: +1,319.75%